Literature DB >> 23052252

Regulatory T cells move in when gliomas say "I Do".

Bryan D Choi1, Peter E Fecci, John H Sampson.   

Abstract

Indoleamine 2,3-dioxygenase (IDO) is an enzyme with known immunosuppressive and tolerogenic effects in cancer. Mounting evidence has associated IDO expression with the induction of regulatory T cells (Treg) and malignant progression. IDO inhibition may therefore provide a promising therapeutic approach for glioblastoma, where the need for novel treatment is great. ©2012 AACR.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23052252      PMCID： PMC3662964          DOI： 10.1158/1078-0432.CCR-12-2801

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

1.  An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme.

Authors:  Abdeljabar El Andaloussi; Maciej S Lesniak
Journal:  Neuro Oncol       Date:  2006-05-24       Impact factor: 12.300

2.  Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.

Authors:  Duane A Mitchell; Xiuyu Cui; Robert J Schmittling; Luis Sanchez-Perez; David J Snyder; Kendra L Congdon; Gary E Archer; Annick Desjardins; Allan H Friedman; Henry S Friedman; James E Herndon; Roger E McLendon; David A Reardon; James J Vredenburgh; Darell D Bigner; John H Sampson
Journal:  Blood       Date:  2011-07-18       Impact factor: 22.113

3.  Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors.

Authors:  Abdeljabar El Andaloussi; Yu Han; Maciej S Lesniak
Journal:  J Neurosurg       Date:  2006-09       Impact factor: 5.115

4.  Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function.

Authors:  Peter E Fecci; Hidenobu Ochiai; Duane A Mitchell; Peter M Grossi; Alison E Sweeney; Gary E Archer; Thomas Cummings; James P Allison; Darell D Bigner; John H Sampson
Journal:  Clin Cancer Res       Date:  2007-04-01       Impact factor: 12.531

5.  Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.

Authors:  Peter E Fecci; Alison E Sweeney; Peter M Grossi; Smita K Nair; Christopher A Learn; Duane A Mitchell; Xiuyu Cui; Thomas J Cummings; Darell D Bigner; Eli Gilboa; John H Sampson
Journal:  Clin Cancer Res       Date:  2006-07-15       Impact factor: 12.531

6.  CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS.

Authors:  F Stephen Hodi; Darryl A Oble; Jan Drappatz; Elsa F Velazquez; Nikhil Ramaiya; Naren Ramakrishna; Arthur L Day; Andrea Kruse; Suzanne Mac Rae; Axel Hoos; Martin Mihm
Journal:  Nat Clin Pract Oncol       Date:  2008-07-29

Review 7.  Immunotherapy of malignant brain tumors.

Authors:  Duane A Mitchell; Peter E Fecci; John H Sampson
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

8.  Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg.

Authors:  Gregoire Biollaz; Luca Bernasconi; Christine Cretton; Ursula Püntener; Karl Frei; Adriano Fontana; Tobias Suter
Journal:  Eur J Immunol       Date:  2009-05       Impact factor: 5.532

9.  IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival.

Authors:  Derek A Wainwright; Irina V Balyasnikova; Alan L Chang; Atique U Ahmed; Kyung-Sub Moon; Brenda Auffinger; Alex L Tobias; Yu Han; Maciej S Lesniak
Journal:  Clin Cancer Res       Date:  2012-08-29       Impact factor: 12.531

10.  A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.

Authors:  John H Sampson; Robert J Schmittling; Gary E Archer; Kendra L Congdon; Smita K Nair; Elizabeth A Reap; Annick Desjardins; Allan H Friedman; Henry S Friedman; James E Herndon; April Coan; Roger E McLendon; David A Reardon; James J Vredenburgh; Darell D Bigner; Duane A Mitchell
Journal:  PLoS One       Date:  2012-02-27       Impact factor: 3.240
View more
  7 in total

Review 1.  T-cell Dysfunction in Glioblastoma: Applying a New Framework.

Authors:  Karolina I Woroniecka; Kristen E Rhodin; Pakawat Chongsathidkiet; Kristin A Keith; Peter E Fecci
Journal:  Clin Cancer Res       Date:  2018-03-28       Impact factor: 12.531

Review 2.  Necrotic reshaping of the glioma microenvironment drives disease progression.

Authors:  Steven M Markwell; James L Ross; Cheryl L Olson; Daniel J Brat
Journal:  Acta Neuropathol       Date:  2022-01-17       Impact factor: 15.887

3.  A road less traveled paved by IDO silencing: Harnessing the antitumor activity of neutrophils.

Authors:  Edwin R Manuel; Don J Diamond
Journal:  Oncoimmunology       Date:  2013-03-01       Impact factor: 8.110

Review 4.  A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy.

Authors:  Dong-Sup Chung; Hye-Jin Shin; Yong-Kil Hong
Journal:  J Immunol Res       Date:  2014-06-09       Impact factor: 4.818

5.  Immune phenotypes predict survival in patients with glioblastoma multiforme.

Authors:  Haouraa Mostafa; Andrej Pala; Josef Högel; Michal Hlavac; Elvira Dietrich; M Andrew Westhoff; Lisa Nonnenmacher; Timo Burster; Michael Georgieff; C Rainer Wirtz; E Marion Schneider
Journal:  J Hematol Oncol       Date:  2016-09-01       Impact factor: 17.388

Review 6.  Immunotherapy Resistance in Glioblastoma.

Authors:  Elaina J Wang; Jia-Shu Chen; Saket Jain; Ramin A Morshed; Alexander F Haddad; Sabraj Gill; Angad S Beniwal; Manish K Aghi
Journal:  Front Genet       Date:  2021-12-17       Impact factor: 4.772

Review 7.  Immunological Evasion in Glioblastoma.

Authors:  Roxana Magaña-Maldonado; Elda Georgina Chávez-Cortez; Nora Karen Olascoaga-Arellano; Mariana López-Mejía; Fernando Manuel Maldonado-Leal; Julio Sotelo; Benjamín Pineda
Journal:  Biomed Res Int       Date:  2016-05-15       Impact factor: 3.411
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.